Apellis Pharmaceuticals, Inc.
APLS
$41.06
$0.040.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 159.58% | 111.31% | 117.99% | 31.46% | 46.39% |
| Total Depreciation and Amortization | -22.01% | -13.30% | -8.11% | -1.91% | -0.44% |
| Total Amortization of Deferred Charges | 23.72% | 60.10% | 131.90% | 428.02% | 591.33% |
| Total Other Non-Cash Items | -12.22% | -16.81% | -16.99% | -17.96% | -12.80% |
| Change in Net Operating Assets | -310.66% | -363.68% | 11.16% | 157.23% | 135.66% |
| Cash from Operations | 555.46% | 151.59% | 138.45% | 101.10% | 98.49% |
| Capital Expenditure | -158.47% | 22.33% | 52.93% | 85.33% | 85.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -158.47% | 22.33% | 40.63% | 81.92% | 83.33% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -9.68% | -52.76% | -79.05% | -76.76% | -85.92% |
| Repurchase of Common Stock | 27.78% | 80.70% | 40.91% | 12.20% | 47.83% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 97.84% | 97.84% | -871.44% |
| Cash from Financing | -79.00% | -94.05% | -97.57% | -96.48% | -62.99% |
| Foreign Exchange rate Adjustments | 935.16% | 289.68% | -88.65% | -2.70% | 30.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42.98% | -8.56% | 249.04% | 103.92% | 107.47% |